Skip to main content

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting · Phase 3 · NCT06073821

Conditions: CLL

At a glance

Research payments reported, 2025
$26.0M
U.S. investigators named
44
Sites paid
58
Planned or actual enrollment
652

About the trial

Sponsor
BeOne Medicines
Tested
Sonrotoclax (drug), Zanubrutinib (drug), Venetoclax (drug), Obinutuzumab (drug)
Dates
Started 2023-11-11; completion 2032-12
Results posted
Not yet

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beigene, Ltd. reported $26.0M in research payments for this study in 2025 (895 payments).

Products named: Brukinsa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.